H. Lundbeck 향후 성장
Future 기준 점검 0/6
H. Lundbeck 의 수익과 수익은 각각 연간 3.4% 및 4.5% 감소할 것으로 예상됩니다. EPS는 연간 3.7% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.3% 로 예상됩니다.
핵심 정보
-4.5%
이익 성장률
-3.73%
EPS 성장률
| Pharmaceuticals 이익 성장 | 10.7% |
| 매출 성장률 | -3.4% |
| 향후 자기자본이익률 | 13.26% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 12 Jun 2026 |
최근 향후 성장 업데이트
분석 기사 • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...분석 기사 • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...분석 기사 • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...Recent updates
분석 기사 • 21h
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
내러티브 업데이트 • Jun 06
HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple
Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.분석 기사 • May 24
H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively
H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...
내러티브 업데이트 • May 23
HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside
Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.분석 기사 • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
내러티브 업데이트 • May 05
HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins
Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.내러티브 업데이트 • Apr 20
HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook
Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.내러티브 업데이트 • Apr 05
HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins
Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.내러티브 업데이트 • Mar 22
HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion
Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.내러티브 업데이트 • Mar 08
HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential
Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.내러티브 업데이트 • Feb 22
HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook
Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.내러티브 업데이트 • Feb 08
HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares
Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.분석 기사 • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...내러티브 업데이트 • Jan 25
HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook
Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.분석 기사 • Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...내러티브 업데이트 • Jan 11
HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook
Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.내러티브 업데이트 • Dec 27
HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements
Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.내러티브 업데이트 • Dec 13
HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares
Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.분석 기사 • Nov 22
The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business
H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...분석 기사 • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)
With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...내러티브 업데이트 • Sep 05
CNS Pipeline And Global Expansion Will Unlock Future Opportunities
With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.분석 기사 • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
새로운 내러티브 • Dec 04
Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth
Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 24,960 | 4,665 | 5,592 | 6,037 | 10 |
| 12/31/2027 | 25,735 | 4,807 | 6,244 | 6,728 | 11 |
| 12/31/2026 | 25,704 | 4,710 | 5,616 | 6,247 | 11 |
| 3/31/2026 | 25,520 | 3,730 | 4,825 | 5,448 | N/A |
| 12/31/2025 | 24,630 | 3,192 | 4,863 | 5,481 | N/A |
| 9/30/2025 | 24,078 | 3,777 | 2,778 | 3,406 | N/A |
| 6/30/2025 | 23,521 | 3,453 | 2,851 | 3,409 | N/A |
| 3/31/2025 | 22,951 | 3,257 | 2,415 | 2,997 | N/A |
| 12/31/2024 | 22,004 | 3,143 | 2,761 | 3,326 | N/A |
| 9/30/2024 | 21,441 | 2,687 | 4,936 | 5,421 | N/A |
| 6/30/2024 | 20,671 | 2,586 | 4,128 | 4,609 | N/A |
| 3/31/2024 | 20,156 | 2,416 | 4,145 | 4,663 | N/A |
| 12/31/2023 | 19,912 | 2,290 | 3,579 | 4,080 | N/A |
| 9/30/2023 | 19,614 | 2,467 | 3,528 | 4,426 | N/A |
| 6/30/2023 | 19,381 | 2,479 | 3,523 | 4,457 | N/A |
| 3/31/2023 | 18,918 | 2,384 | 3,292 | 4,102 | N/A |
| 12/31/2022 | 18,246 | 1,916 | 2,699 | 3,519 | N/A |
| 9/30/2022 | 17,619 | 1,603 | 2,051 | 2,615 | N/A |
| 6/30/2022 | 16,913 | 1,236 | 1,744 | 2,313 | N/A |
| 3/31/2022 | 16,398 | 1,109 | 1,344 | 1,959 | N/A |
| 12/31/2021 | 16,299 | 1,318 | 1,660 | 2,272 | N/A |
| 9/30/2021 | 16,521 | 1,873 | 2,405 | 2,949 | N/A |
| 6/30/2021 | 16,971 | 1,965 | 2,379 | 2,912 | N/A |
| 3/31/2021 | 17,381 | 2,110 | 3,263 | 3,757 | N/A |
| 12/31/2020 | 17,672 | 1,581 | 3,359 | 3,837 | N/A |
| 9/30/2020 | 17,818 | 904 | 2,713 | 3,171 | N/A |
| 6/30/2020 | 17,490 | 1,242 | 2,910 | 3,354 | N/A |
| 3/31/2020 | 17,366 | 1,507 | 1,502 | 1,960 | N/A |
| 12/31/2019 | 17,036 | 2,313 | N/A | 2,609 | N/A |
| 9/30/2019 | 16,811 | 3,091 | N/A | 3,621 | N/A |
| 6/30/2019 | 17,309 | 3,395 | N/A | 3,462 | N/A |
| 3/31/2019 | 17,766 | 3,606 | N/A | 4,815 | N/A |
| 12/31/2018 | 18,117 | 3,907 | N/A | 5,981 | N/A |
| 9/30/2018 | 18,313 | 3,806 | N/A | 5,922 | N/A |
| 6/30/2018 | 18,028 | 3,627 | N/A | 6,197 | N/A |
| 3/31/2018 | 17,608 | 3,236 | N/A | 5,397 | N/A |
| 12/31/2017 | 17,234 | 2,624 | N/A | 4,045 | N/A |
| 9/30/2017 | 17,007 | 2,544 | N/A | 3,731 | N/A |
| 6/30/2017 | 16,607 | 1,988 | N/A | 3,551 | N/A |
| 3/31/2017 | 16,075 | 1,612 | N/A | 3,420 | N/A |
| 12/31/2016 | 15,634 | 1,211 | N/A | 3,126 | N/A |
| 9/30/2016 | 15,202 | 290 | N/A | 4,158 | N/A |
| 6/30/2016 | 14,923 | -1,289 | N/A | 2,755 | N/A |
| 3/31/2016 | 14,801 | -5,427 | N/A | 936 | N/A |
| 12/31/2015 | 14,594 | -5,694 | N/A | 197 | N/A |
| 9/30/2015 | 14,108 | -5,879 | N/A | -1,330 | N/A |
| 6/30/2015 | 13,625 | -4,615 | N/A | -464 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: HLUN B 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -4.5%).
수익 vs 시장: HLUN B 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -4.5%).
고성장 수익: HLUN B 의 수익은 향후 3년간 감소할 것으로 예상됩니다.
수익 대 시장: HLUN B 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -3.4%).
고성장 매출: HLUN B 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -3.4%).
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: HLUN B의 자본 수익률은 3년 후 13.3%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/17 11:32 |
| 종가 | 2026/06/17 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
H. Lundbeck A/S는 33명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Emily Field | Barclays |
| Charles Pitman | Barclays |
| Rosie Turner | Barclays |